L-Carnitine is an osmotic agent suitable for peritoneal dialysis

Kidney International

Volumn 80, Issue 6, 2011, Pages 645-654

  Bonomini, Mario ^a   Pandolfi, Assunta ^a   Di Liberato, Lorenzo ^a   Di Silvestre, Sara ^a   Cnops, Yvette ^b   Di Tomo, Pamela ^a   D'Arezzo, Mario ^a   Monaco, Maria P ^a   Giardinelli, Annalisa ^a   Di Pietro, Natalia ^a   Devuyst, Olivier ^b   Arduini, Arduino ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^c Université Catholique de Louvain Medical School ^*  (Switzerland)

Author keywords

endothelium; fibroblast; peritoneal dialysis; ultrafiltration; water channels

Indexed keywords

AQUAPORIN 1; CARNITINE; GLUCOSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CASE REPORT; CELL CULTURE; CELL VIABILITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSMOLARITY; OSMOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TOXICITY TESTING; ULTRAFILTRATION; WATER TRANSPORT;

EID: 80052270963     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.117     Document Type: Article

References (45)

1. Chaundary K, Khanna R. Biocompatible peritoneal dialysis solutions: do we have one? Clin J Am Soc Nephrol 2010; 5: 723-732.
2. Twardowski ZJ, Khanna R, Nolph KD. Osmotic agents and ultrafiltration in peritoneal dialysis. Nephron 1986; 42: 93-101. (Pubitemid 16187218)
3. Diaz-Buxo JA, Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007; 27: 16-30. (Pubitemid 46403276)
4. Holmes CJ. Glucotoxicity in peritoneal dialysis-solutions for the solution!. Adv Chronic Kidney Dis 2007; 14: 269-278. (Pubitemid 46977289)
5. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344. (Pubitemid 37052381)
6. Selby NM, Fialova J, Burton JO et al. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transplant 2007; 22: 870-879. (Pubitemid 46351699)
7. Freida P, Wilkiw M, Jenkins S et al. The contribution of combined crystalloid and colloid osmosis to fluid and sodium management in peritoneal dialysis. Kidney Int 2008; 73: S102-S111. (Pubitemid 351466526)
8. Jones M, Hagen T, Boyle CA et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32: 761-769. (Pubitemid 28516306)
9. Johnson DW, Agar J, Collins J et al. Recommendations for the use of icodextrin in peritoneal dialysis patients. Nephrology 2003; 8: 1-7. (Pubitemid 36237943)
10. Bremer J. Carnitine-metabolism and function. Physiol Rev 1983; 63: 1420-1480.
11. Ramsay RR, Arduini A. The carnitine acyltransferases and their role in modulating acyl-CoA pools. Arch Biochem Biophys 1993; 302: 307-314. (Pubitemid 23212675)
12. Ramsay RR, Zammit V. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med 2004; 25: 475-493. (Pubitemid 39195072)
13. Budavari SK, Smith KA, Heckelman P et al. (eds) The Merck Index: An Encyclopedia of Drugs, Chemicals, and Biologicals, 12th edn. Merck & CO: Whitehouse Station, NJ, 1996, pp 302-303.
14. Yeung CH, Anapolski M, Setiawan I et al. Effects of putative epididymal osmolytes on sperm volume regulation of fertile and infertile c-ros transgenic mice. J Androl 2004; 25: 216-223. (Pubitemid 38240663)
15. Corrales RM, Luo L, Chang EY et al. Effects of osmoprotectants on hyperosmolar stress in cultured human corneal epithelial cells. Cornea 2008; 27: 574-579.
16. Brass EP, Adler S, Sietsema KE et al. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001; 37: 1018-1028. (Pubitemid 32436575)
17. Moretti S, Alesse E, Di Marzio L et al. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood 1998; 91: 3817-3824. (Pubitemid 28225750)
18. Gaggiotti E, Arduini A, Bonomini M et al. Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits). Int J Artif Organs 2005; 28: 177-187. (Pubitemid 40485218)
19. Ni J, Cnops Y, Debaix H et al. Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse. Kidney Int 2005; 67: 2021-2031. (Pubitemid 40577741)
20. Tsilibary E. Microvascular basement membranes in diabetes mellitus. J Pathol 2003; 200: 537-547.
21. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23: 117-145. (Pubitemid 36241095)
22. Pannekeet MM, Mulder JB, Weening JJ et al. Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Perit Dial Int 1996; 16: S54-S57. (Pubitemid 26159711)
23. Devuyst O, Nielsen S, Cosyns JP et al. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 1998; 275: H234-H242.
24. Wieslander AP, Nordin MK, Kjellstrand PT et al. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991; 40: 77-79.
25. Churchill DN, Thorpe KE, Nolph KD et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous ambulatory peritoneal dialysis patients. The Canada-USA (CANUSA) peritoneal dialysis study group. J Am Soc Nephrol 1998; 9: 1285-1292. (Pubitemid 28283893)
26. Davies SJ, Brown EA, Reigel W et al. What is the link between poor ultrafiltration and increased mortality in anuric patients on automated peritoneal dialysis? Analysis of data from EAPOS. Perit Dial Int 2006; 26: 458-465. (Pubitemid 44339978)
27. Davies SJ, Phillips L, Griffiths AM et al. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54: 2207-2217. (Pubitemid 28533651)
28. Davies SJ. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Kidney Int 2006; 70(Suppl 103): S76-S83. (Pubitemid 44684780)
29. Mutomba MC, Yaun H, Konyavko M et al. Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. FEBS Lett 2000; 478: 19-25. (Pubitemid 30462251)
30. Andrieu-Abadie N, Jaffrézou JP, Hatem S et al. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J 1999; 13: 1501-1510. (Pubitemid 29411782)
31. Zou X, Sadovova N, Patterson TA et al. The effects of L-carnitine on the combination of, inhalation anesthetic-induced developmental, neuronal apoptosis in the rat frontal cortex. Neuroscience 2008; 151: 1053-1065.
32. Xie H, Tang SY, Li H et al. L-carnitine protects against apoptosis of murine MC3T3-E1 osteoblastic cells. Amino Acids 2008; 35: 419-423.
33. Rippe B, Venturoli D, Simonsen O et al. Fluid and electrolyte transport across the peritoneal membrane during CAPD. Perit Dial Int 2004; 24: 10-27. (Pubitemid 38886091)
34. Ni J, Verbavatz JM, Rippe A et al. Aquaporin-1 plays and essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int 2006; 69: 1518-1525.
35. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 2010; 21: 1077-1085.
36. Morss AS, Edelman ER. Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem 2007; 282: 14635-14644. (Pubitemid 47100452)
37. Lai KN, Li FK, Lan HY et al. Expression of aquaporin-1 in human peritoneal mesothelial cells and its upregulation by glucose in vitro. J Am Soc Nephrol 2001; 12: 1036-1045. (Pubitemid 32378345)
38. Hamilton JJ, Hahn P. Carnitine and carnitine esters in rat bile and human duodenal fluid. Can J Physiol Pharmacol 1987; 65: 1816-1820. (Pubitemid 18018662)
39. Fuda F, Narayan SB, Squires RH et al. Bile acylcarnitine profiles in pediatric liver disease do not interfere with the diagnosis of long-chain fatty acid oxidation defects. Clin Chim Acta 2006; 367: 185-188.
40. Arduini A, Bonomini M, Savica V et al. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 2008; 120: 149-156.
41. Biolo G, Stulle M, Bianco F et al. Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 2008; 23: 991-997. (Pubitemid 351767549)
42. Ma T, Yang B, Gillespie A et al. Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. J Biol Chem 1998; 273: 4296-4299. (Pubitemid 28103161)
43. Ni J, Moulin P, Gianello P et al. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14: 3205-3216. (Pubitemid 37509296)
44. Sun D, Cree MG, Zhang X et al. Measurement of stable isotopic enrichment and concentration of long-chain acyl-carnitines in tissue by HPLC-MS. J Lipid Res 2006; 47: 431-439. (Pubitemid 43276929)
45. Gorfien S, Spector A, de Luca D et al. Growth and physiological functions of vascular endothelial cells in a new serum-free medium (SFM). Exp Cell Res 1993; 206: 291-301. (Pubitemid 23212947)